trending Market Intelligence /marketintelligence/en/news-insights/trending/fnxyfib8n4hiix0uudqfjw2 content esgSubNav
In This List

AMAG Pharmaceuticals, Sandoz settle anemia drug patent case

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


AMAG Pharmaceuticals, Sandoz settle anemia drug patent case

AMAG Pharmaceuticals Inc. and Novartis AG's Sandoz Inc. unit agreed to settle their patent dispute involving the AMAG's anemia drug Feraheme.

AMAG received a notification from the U.S. Food and Drug Administration when Sandoz filed a Paragraph IV abbreviated new drug application for its generic version of the drug in 2016. In the filing, the generic-drug company said the generic copy does not infringe the listed patents in the FDA's Orange Book, or that such patents are invalid or unenforceable.

If Sandoz wins the FDA's approval by a certain date, the Novartis unit may launch the generic copy July 15, 2021, or earlier under certain circumstances. Sandoz will also pay AMAG a royalty on the generic's sales until the last Feraheme patent listed in the Orange Book expires.

However, if the U.S. regulator rejects Sandoz's application, the company may launch the approved generic version July 15, 2022, for a one-year period.

AMAG believes the settlement allows the continued advancement of Feraheme in the U.S. iron market.